Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center

• Published in: Hematology (Luxembourg) 2024-12, Vol.29 (1), p.2431958
• Main Authors: Xu, Shuiqing, Chen, Wenming, Li, Yanchen
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; daratumumab-based; daratumumab-free; Female; Humans; Male; Middle Aged; Multiple myeloma; Multiple Myeloma - drug therapy; Multiple Myeloma - mortality; newly-diagnosed; paraskeletal plasmacytomas; Plasmacytoma - diagnosis; Plasmacytoma - drug therapy; Plasmacytoma - mortality; Retrospective Studies; risk factors
• ISSN: 1607-8454; 1607-8454
• DOI: 10.1080/16078454.2024.2431958

To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs). The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free regimen was divided into group B. The risk factors, efficacy, and overall survival (OS) were compared between the two groups. The results of univariate COX regression analysis showed that only the grouping and creatinine were statistically significant. The HR value of group A was 0.30(0.10-0.88,  = 0.029), which was a protective factor for patient survival, and the HR value of creatinine was 1.00(1.00-1.01,  = 0.026), which was a risk factor for patient survival. There was a statistically significant difference in efficacy between the two groups,  = 0.025